Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Cancer. A bull's eye for targeted lung cancer therapy.

Minna JD, Gazdar AF, Sprang SR, Herz J.

Science. 2004 Jun 4;304(5676):1458-61. No abstract available.

PMID:
15178790
2.
3.
4.
5.

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

Zhang X, Chang A.

J Med Genet. 2007 Mar;44(3):166-72. Epub 2006 Dec 8. Review.

6.

[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].

Madelaine J, Cadranel J, Zalcman G.

Rev Mal Respir. 2004 Nov;21(5 Pt 1):881-5. Review. French. No abstract available.

PMID:
15622331
7.

The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.

Dowell JE, Minna JD.

Nat Clin Pract Oncol. 2004 Nov;1(1):2-3. Review. No abstract available.

PMID:
16264773
8.

[Personalized treatment in non-small cell lung cancer].

Campos-Parra AD, Cruz-Rico G, Arrieta O.

Rev Invest Clin. 2012 Jul-Aug;64(4):377-86. Review. Spanish. No abstract available.

PMID:
23227588
9.

[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].

Qiao J, Chen W.

Zhongguo Fei Ai Za Zhi. 2011 Oct;14(10):806-10. doi: 10.3779/j.issn.1009-3419.2011.10.07. Review. Chinese. No abstract available.

10.

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.

Heigener DF, Reck M.

Adv Ther. 2011 Feb;28(2):126-33. doi: 10.1007/s12325-010-0096-4. Epub 2010 Dec 16. Review.

PMID:
21181318
11.

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.

Price N, Belani C.

Clin Lung Cancer. 2005 Jan;6(4):214-6. Review. No abstract available.

PMID:
15694012
12.

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Sequist LV, Bell DW, Lynch TJ, Haber DA.

J Clin Oncol. 2007 Feb 10;25(5):587-95. Review.

PMID:
17290067
13.

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].

Shi Y, Sun Y, Ding C, Wang Z, Wang C, Wang Z, Bai C, Bai C, Feng J, Liu X, Li F, Yang Y, Shu Y, Wu M, He J, Zhang Y, Zhang S, Chen G, Luo H, Luo R, Zhou C, Zhou Y, Pang Q, Zhao H, Zhao Q, Gu A, Ling Y, Huang C, Han B, Jiao S, Jian H.

Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):397-400. doi: 10.3779/j.issn.1009-3419.2015.07.01. Chinese. No abstract available.

14.

Tyrosine kinase signal transduction inhibitors. Clinical trials.

Scagliotti GV.

Suppl Tumori. 2002 Jul-Aug;1(4):S34-6. Review. No abstract available.

PMID:
12415814
15.
16.

Epidermal growth factor receptor inhibition and non-small cell lung cancer.

von Eyben FE.

Crit Rev Clin Lab Sci. 2006;43(4):291-323. Review.

PMID:
16769595
17.

Targeting the epidermal growth factor receptor a new strategy in cancer treatment.

Gianni L, Grasselli G.

Suppl Tumori. 2002 Jul-Aug;1(4):S60-1. Review. No abstract available.

PMID:
12415824
18.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Ladanyi M, Pao W.

Mod Pathol. 2008 May;21 Suppl 2:S16-22. doi: 10.1038/modpathol.3801018. Review.

19.

The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Comis RL.

Oncologist. 2005 Aug;10(7):467-70. Review. No abstract available.

20.

[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].

Shimizu J, Horio Y, Mitsudomi T.

Gan To Kagaku Ryoho. 2005 Nov;32(12):1879-85. Review. Japanese.

PMID:
16282720

Supplemental Content

Support Center